Qiliqiangxin Capsule in Patients with Chronic Heart Failure Complicated by Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials
Kaijuan Wang , Jinhao Xu , Xiangying Zheng , Fengshuo Chang , Jingen Li
Advances in World Medical Research ›› 2026, Vol. 2 ›› Issue (3) : 49 -77.
To explore the clinical value and potential risk of Qiliqiangxin Capsule, we designed a systematic review and meta-analysis on randomized controlled trials (RCTs), targeting patients diagnosed with both chronic heart failure and coronary artery disease. Our search included eight commonly used databases, focusing on studies that assessed the effectiveness of Qiliqiangxin Capsule and guideline-directed medical therapy for patients whose condition was chronic heart failure complicated by coronary artery disease. We conducted the meta-analysis employing the meta and metafor packages running under R 4.5.3, whereas the risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. After systematic screening procedure, we included 17 studies, involving 2000 eligible patients. The results showed that Qiliqiangxin Capsule combination treatment reduced the occurrences of the primary outcome [RR=0.38,95%CI (0.23,0.63)], left ventricular ejection fraction (LVEF) [MD=5.39,95%CI (4.62,6.16)], left ventricular end-diastolic diameter (LVEDD) [MD=-4.86,95% CI(-6.20,-3.51)], N-terminal B-type natriuretic peptide precursor (NT-proBNP) levels [SMD = -0.82, 95% CI (-0.97, -0.67)], the 6-minute walk test distance (6MWD) [MD=39.05,95%CI(19.90,58.20)], and the clinical efficacy [RR = 1.20, 95% CI (1.14, 1.25)] were also significantly improved. As for the safety evaluation, the incidence of adverse events was not found to differ meaningfully [RR = 0.95, 95% CI (0.60, 1.50) ]. The combination of Qiliqiangxin Capsule and guideline-directed medical therapy can safely and effectively improve the heart failure rehospitalization and all-cause mortality in patients with chronic heart failure complicated by coronary artery disease, improve cardiac performance, increase physical capacity. However, further large sample trials are required to confirm the results.
Qiliqiangxin Capsule / Chronic Heart Failure / Coronary Artery Disease / Meta-Analysis
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
Chinese Society of Cardiology, Chinese Medical Association, Chinese College of Cardiovascular Physician, C. H. F. a. O. C. M. D. A., and |
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
/
| 〈 |
|
〉 |